|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: BTNL3 |
Gene summary for BTNL3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | BTNL3 | Gene ID | 10917 |
| Gene name | butyrophilin like 3 | |
| Gene Alias | BTN9.1 | |
| Cytomap | 5q35.3 | |
| Gene Type | protein-coding | GO ID | GO:0001816 | UniProtAcc | Q6UXE8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10917 | BTNL3 | HTA11_3410_2000001011 | Human | Colorectum | AD | 4.24e-05 | -2.33e-01 | 0.0155 |
| 10917 | BTNL3 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.50e-02 | 5.27e-01 | -0.1808 |
| 10917 | BTNL3 | HTA11_78_2000001011 | Human | Colorectum | AD | 1.86e-02 | 4.34e-01 | -0.1088 |
| 10917 | BTNL3 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.81e-05 | 4.50e-01 | -0.1954 |
| 10917 | BTNL3 | HTA11_411_2000001011 | Human | Colorectum | SER | 1.62e-02 | 1.12e+00 | -0.2602 |
| 10917 | BTNL3 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.92e-03 | 5.99e-01 | -0.1526 |
| 10917 | BTNL3 | HTA11_10711_2000001011 | Human | Colorectum | AD | 1.29e-03 | -2.44e-01 | 0.0338 |
| 10917 | BTNL3 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 3.60e-05 | -2.35e-01 | 0.3005 |
| 10917 | BTNL3 | A001-C-207 | Human | Colorectum | FAP | 4.69e-04 | -2.36e-01 | 0.1278 |
| 10917 | BTNL3 | A015-C-203 | Human | Colorectum | FAP | 1.50e-06 | -2.34e-01 | -0.1294 |
| 10917 | BTNL3 | A002-C-201 | Human | Colorectum | FAP | 1.06e-02 | -1.51e-01 | 0.0324 |
| 10917 | BTNL3 | A002-C-203 | Human | Colorectum | FAP | 1.37e-02 | -1.50e-01 | 0.2786 |
| 10917 | BTNL3 | A001-C-119 | Human | Colorectum | FAP | 5.17e-05 | -2.44e-01 | -0.1557 |
| 10917 | BTNL3 | A001-C-108 | Human | Colorectum | FAP | 1.63e-03 | -1.88e-01 | -0.0272 |
| 10917 | BTNL3 | A002-C-205 | Human | Colorectum | FAP | 1.92e-09 | -2.44e-01 | -0.1236 |
| 10917 | BTNL3 | A001-C-104 | Human | Colorectum | FAP | 2.37e-07 | -2.16e-01 | 0.0184 |
| 10917 | BTNL3 | A015-C-005 | Human | Colorectum | FAP | 2.87e-03 | -1.97e-01 | -0.0336 |
| 10917 | BTNL3 | A015-C-006 | Human | Colorectum | FAP | 9.07e-06 | -2.44e-01 | -0.0994 |
| 10917 | BTNL3 | A015-C-106 | Human | Colorectum | FAP | 2.65e-02 | -1.85e-01 | -0.0511 |
| 10917 | BTNL3 | A002-C-114 | Human | Colorectum | FAP | 4.19e-04 | -1.90e-01 | -0.1561 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| BTNL3 | SNV | Missense_Mutation | c.337N>A | p.Gly113Arg | p.G113R | Q6UXE8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD | |
| BTNL3 | SNV | Missense_Mutation | novel | c.1142N>A | p.Arg381Lys | p.R381K | Q6UXE8 | protein_coding | tolerated(0.07) | benign(0.011) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| BTNL3 | SNV | Missense_Mutation | c.353C>A | p.Ser118Tyr | p.S118Y | Q6UXE8 | protein_coding | deleterious(0.01) | probably_damaging(0.986) | TCGA-BH-A0B8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |
| BTNL3 | insertion | Frame_Shift_Ins | rs757227190 | c.1200dupC | p.Ser401GlnfsTer14 | p.S401Qfs*14 | Q6UXE8 | protein_coding | TCGA-A2-A0T2-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | xeloda | PD | ||
| BTNL3 | insertion | Frame_Shift_Ins | novel | c.198_199insAGTC | p.Tyr67SerfsTer11 | p.Y67Sfs*11 | Q6UXE8 | protein_coding | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| BTNL3 | insertion | Frame_Shift_Ins | rs757227190 | c.1193_1194insC | p.Ser401GlnfsTer14 | p.S401Qfs*14 | Q6UXE8 | protein_coding | TCGA-BH-A0BR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| BTNL3 | deletion | Frame_Shift_Del | novel | c.756delN | p.Met254Ter | p.M254* | Q6UXE8 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| BTNL3 | SNV | Missense_Mutation | novel | c.998N>A | p.Ser333Tyr | p.S333Y | Q6UXE8 | protein_coding | deleterious(0.02) | probably_damaging(0.995) | TCGA-VS-A952-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| BTNL3 | SNV | Missense_Mutation | novel | c.998N>A | p.Ser333Tyr | p.S333Y | Q6UXE8 | protein_coding | deleterious(0.02) | probably_damaging(0.995) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| BTNL3 | SNV | Missense_Mutation | rs771112486 | c.286N>T | p.Arg96Cys | p.R96C | Q6UXE8 | protein_coding | tolerated(0.09) | possibly_damaging(0.465) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |